Vertex Pharmaceuticals, Inc.

NASDAQ:VRTX  
203.81
-0.64 (-0.31%)
4:42:25 PM EDT: $202.09 -1.72 (-0.84%)
Products

Vertex Announces U.S. FDA Approval For Trikafta® (Elexacaftor/Tezacaftor/Ivacaftor And Ivacaftor) In Children With Cystic Fibrosis Ages 6 Through 11 With Certain Mutations

Published: 06/09/2021 12:31 GMT
Vertex Pharmaceuticals, Inc. (VRTX) - Vertex Announces U.S. FDA Approval for Trikafta® (elexacaftor/tezacaftor/ivacaftor and Ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 With Certain Mutations.
Vertex Pharmaceuticals Inc - an Additional Dosage Strength of Trikafta Tablets is Now Available in Connection With Approval.
Vertex -with Approval, About 1,500 Children With 1 Minimal Function Mutation, One F508del Mutation Have Medicine to Treat Underlying Cause of Disease.